BRPI0510760A - método para administrar a um paciente uma composição, composição tópica, e, emplastro - Google Patents

método para administrar a um paciente uma composição, composição tópica, e, emplastro

Info

Publication number
BRPI0510760A
BRPI0510760A BRPI0510760-1A BRPI0510760A BRPI0510760A BR PI0510760 A BRPI0510760 A BR PI0510760A BR PI0510760 A BRPI0510760 A BR PI0510760A BR PI0510760 A BRPI0510760 A BR PI0510760A
Authority
BR
Brazil
Prior art keywords
composition
propynoperhydropurine
tricyclic
effective amount
pharmaceutical compositions
Prior art date
Application number
BRPI0510760-1A
Other languages
English (en)
Inventor
Nestor Antonio Lagos Wilson
Original Assignee
Phytotox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotox Ltd filed Critical Phytotox Ltd
Publication of BRPI0510760A publication Critical patent/BRPI0510760A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

MéTODO PARA ADMNISTRAR A UM PACIENTE UMA COMPOSIçãO, COMPOSIçãO TóPICA, E, EMPLASTRO Composições farmacêuticas para interferir com a transmissão neuronal compreendendo uma quantidade eficaz de pelo menos uma 3,4-propinoperidropurina tricíclica são divulgadas. Preparações para o rejuvenescimento facial são fornecidas que compreendem uma quantidade eficaz da composição da invenção e um creme facial. Métodos de interferir com a transmissão neuronal que compreende a aplicação tópica de uma quantidade eficaz das composições farmacêuticas da invenção são fornecidos. Em um outro aspecto da invenção, quantidades eficazes das composições farmacêuticas e um sistema terapêutico transdérmico são fornecidos para a administração transdérmica de pelo menos uma 3,4-propinoperidropurina triciclica. A composição farmacêutica contém pelo menos uma 3,4-propinoperidropurina tricicica e pode ser formulada para a liberação de medicamento transdérmica. O sistema de liberação de medicamento transdérmica pode ser um compósito laminado que compreende uma camada de suporte, um reservatório de medicamento e um meio para prender o compósito à pele.
BRPI0510760-1A 2004-05-07 2005-05-06 método para administrar a um paciente uma composição, composição tópica, e, emplastro BRPI0510760A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56911204P 2004-05-07 2004-05-07
PCT/US2005/015819 WO2005110418A2 (en) 2004-05-07 2005-05-06 Transdermal administration of phycotoxins

Publications (1)

Publication Number Publication Date
BRPI0510760A true BRPI0510760A (pt) 2007-11-20

Family

ID=35394660

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510760-1A BRPI0510760A (pt) 2004-05-07 2005-05-06 método para administrar a um paciente uma composição, composição tópica, e, emplastro

Country Status (10)

Country Link
US (1) US8377951B2 (pt)
EP (1) EP1796676B1 (pt)
JP (1) JP2007538010A (pt)
CN (1) CN101123967A (pt)
AU (1) AU2005244096B2 (pt)
BR (1) BRPI0510760A (pt)
CA (1) CA2607206C (pt)
ES (1) ES2568953T3 (pt)
MX (1) MXPA06012960A (pt)
WO (1) WO2005110418A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536269A (ja) * 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009143174A2 (en) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Chemical permeation enhancers enhance nerve blockade by toxins
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
CA2760946C (en) * 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置
WO2013122637A1 (en) * 2012-02-17 2013-08-22 Capriotti Joseph Antifungal compositions for the treatment of skin and nails
EP2638908A1 (en) * 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
US20130251770A1 (en) * 2012-03-22 2013-09-26 Revance Therapeutics, Inc. Method of Treatment of Wrinkles Using Topical Chemodenervating Agents
RS58750B1 (sr) 2013-03-15 2019-06-28 Childrens Medical Ct Corp Kombinovane formulacije neosaksitoksina za produženu lokalnu anesteziju
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
US11338308B2 (en) * 2018-08-09 2022-05-24 Kao Corporation Method for producing wearable coating
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957966A (en) 1972-05-19 1976-05-18 Gaf Corporation Stabilized vitamin food coatings
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029794A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US4001413A (en) 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5246705A (en) 1992-04-08 1993-09-21 Cygnus Therapeutic System Occlusive, elastomeric backing materials in transdermal drug delivery systems, and associated methods of manufacture and use
US5562907A (en) 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP0758900B1 (en) 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
US5504117A (en) 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
JP3517031B2 (ja) 1995-06-09 2004-04-05 日清紡績株式会社 生物学的活性物質の分析法
US5837265A (en) 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CN1081034C (zh) 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
WO1998043619A2 (en) 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
KR100544060B1 (ko) 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
WO2000024419A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6299902B1 (en) 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
CN1203857C (zh) 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1240702C (zh) 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
CN1382443A (zh) 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
CN1269482C (zh) 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
CN1194693C (zh) 2002-01-11 2005-03-30 中国科学院海洋研究所 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用
US20030224020A1 (en) 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
AU2003298837A1 (en) 2002-12-02 2004-06-23 Massachusetts Institute Of Technology Prolonged suppression of electrical activity in excitable tissues
JP2007536269A (ja) 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法

Also Published As

Publication number Publication date
CN101123967A (zh) 2008-02-13
US8377951B2 (en) 2013-02-19
CA2607206A1 (en) 2005-11-24
EP1796676B1 (en) 2016-03-09
ES2568953T3 (es) 2016-05-05
EP1796676A2 (en) 2007-06-20
AU2005244096B2 (en) 2011-03-17
CA2607206C (en) 2016-06-14
JP2007538010A (ja) 2007-12-27
HK1109332A1 (zh) 2008-06-06
WO2005110418A3 (en) 2007-06-07
AU2005244096A1 (en) 2005-11-24
US20080045553A1 (en) 2008-02-21
MXPA06012960A (es) 2007-06-12
EP1796676A4 (en) 2008-06-25
WO2005110418A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0510760A (pt) método para administrar a um paciente uma composição, composição tópica, e, emplastro
BRPI0608249A2 (pt) formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
BRPI0511235A (pt) preparado tópico e método para a administração transdérmica e localização de agentes terapêuticos
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0719115B8 (pt) sistema terapêutico transdérmico para administração de buprenorfina à pele
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
WO2010070675A8 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
BRPI0417437A (pt) dispositivo para inibição da absorção, dispositivo para remoção de agente fisiologicamente ativo e dispositivo para redução do efeito de overdose
ECSP056076A (es) Sistema de suministro para droga y terapia celular
BR112012007550A8 (pt) Composição em gel, produtos para tratamento de verruga, e de calos/calosidades, método para tratar uma doença de pele, dispensador para administrar uma composição para tratar uma doença de pele em um indivíduo, e, método para aprimorar administração tópica de ácido salicílico a um indivíduo
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
AU2019420039B2 (en) Laminated adhesive sheet for skin
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BRPI0415215B8 (pt) uso de polifenol na preparação de medicamento
BR0316275A (pt) Administração dérmica de um inibidor seletivo de ciclooxigenase-2, solúvel em água, por exemplo, parecoxibe e valdecoxibe
WO2004073622A3 (en) Novel therapeutic method and compositions for topical administration
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
MX2010009578A (es) Metodos para incrementar el espesor epidermico de la piel mediante la administracion topica de un compuesto de vitamina d que contiene 19-nor.
US20100098732A1 (en) Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or aging skin, and/or hair loss
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
WO2010057117A3 (en) Topical transdermal drug delivery compositions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.